About this trial
“20% of patients of childbearing age who receive ICIs for cancer will have a reduction in any reproductive parameter due to either reduced gametogenesis; autoantibody formation or endocrine dysfunction as a result of ICI therapy, identified within the first 2 years of ICI therapy.
This study will test this hypothesis by the assessment of AMH level, AFC, in females and sperm concentration, motility, morphology and anti-sperm antibodies in males at prespecified timepoints in the first 1-2 years post ICI therapy.”
Patient Profile
Where’s this trial being run?
Beaumont Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | IMMUNO FERTILITY |
|---|---|
| Number: | 22-22 |
| Full Title: | A prospective observational study investigating the impact of immune checkpoint inhibitors for cancer on fertility in males and females of childbearing age |
| Principal Investigator: | Prof Jarushka Naidoo |
|---|---|
| Type: | |
| Sponsor: | Investigator Led Trial |
| Recruitment Started: |
Global: N/A Ireland: Yes |
| Global Recruitment Target: | N/A |
|---|---|
| Ireland Recruitment Target: | 88 - Open until late 2024 |